HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

Phase 1/2 Recruiting 62 enrolled The Methodist Hospital Research Institute

NaSingle-groupOpen-labelTreatment

Summary

Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA).

Timeline

Start: 2018-02-28
Primary completion: 2026-12-31
Completion: 2026-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HSV-Tk	Cell therapy	—	Other

HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

Summary

Timeline

Drugs

Indications